case_images: PMC9869123_01
case_images: Treatment history of this HR+/HER2- breast cancer patient receiving abemaciclib combined with exemestane after prior progression on palbociclib and fulvestrant.
case_images: fonc-12-1022913-g001.jpg
case_images: PMC9869123_01_fonc-12-1022913-g001.jpg
case_images: f1
case_images: Her treatment is summarized in  Figure 1 . TP53 p.H214Lfs*33 frame shift mutation in exon 6 were found (Figure 1). The plasma tumor mutation burden (TMB) was 4.1 mutations/megabase [mut/Mb].
case_images: The changes in serum CA153 (U/ml) during the treatment of abemaciclib and exemestane.
case_images: fonc-12-1022913-g002.jpg
case_images: PMC9869123_01_fonc-12-1022913-g002.jpg
case_images: f2
case_images: After 1 month, CA153 levels decreased to normal ( Figure 2 ), and lung lesions were stable.
case_images: The changes in images during the treatment of abemaciclib and exemestane. (A) The baseline of lung metastasis at the beginning of abemaciclib and exemestane. (B) The lung lesions were stable after 6 months treatment. (C) The lung lesions progressed after 16 months of treatment. (D) Liver metastasis was found after 16 months of treatment.
case_images: fonc-12-1022913-g003.jpg
case_images: PMC9869123_01_fonc-12-1022913-g003.jpg
case_images: f3
case_images: Sixteen months (on 12-02-2021) later, she was short of breath, and chest CT scan showed progression of pulmonary lesions with liver metastatic lesions ( Figure 3 ).